Community-Acquired Pneumonia: The U.S. Perspective

Michael S. Niederman

doi:10.1055/s-0029-1202937

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2009; 30(2): 179-188
DOI: 10.1055/s-0029-1202937

Community-Acquired Pneumonia: The U.S. Perspective

Michael S. Niederman¹ ^, ²

¹Division of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, Winthrop University Hospital, Mineola, New York
²Department of Medicine, SUNY at Stony Brook, Stony Brook, New York

Abstract

ABSTRACT

Community-acquired pneumonia (CAP) is a common and serious problem in the United States, and the sixth leading cause of death in those over age 65. Not only has short-term mortality been evaluated, but 1-year mortality may be as high as 40% in Medicare patients who have been admitted to the hospital with CAP. In the United States, guidelines for CAP management have been available since 1993, with the most recent version published in 2007 as a joint effort of the Infectious Diseases Society of America and the American Thoracic Society. The current U.S. guidelines take into consideration unique bacteriologic patterns in the United States, particularly focusing on the role of drug-resistant pneumococcus, atypical pathogens, and methicillin-resistant Staphylococcus aureus, which explains why U.S. recommendations for therapy differ from those in Europe and the United Kingdom. Notable differences in the U.S. approach to CAP compared with elsewhere include not only a unique set of bacteriologic considerations and therapy recommendations that follow these concerns but also a different approach to assessing severity of illness and recommended diagnostic testing, as well as the inclusion of performance measures to optimize disease management. Compared with European and British guidelines, the U.S. therapy of CAP has a greater emphasis on the role of atypical pathogens, a more defined role for fluoroquinolones as first-line therapy, less reliance on oral therapy for hospitalized patients, and less regard for the value of certain β-lactam agents.

KEYWORDS

Pneumonia - drug-resistance - Streptococcus pneumoniae - Staphylococcus aureus - performance measures - guidelines - prognostic scoring - diagnostic testing

Volltext

Referenzen

REFERENCES

1 Mandell L A, Wunderink R G, Anzueto A et al.. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 S27-S72
2 American Thoracic Society .Trends in pneumonia and influenza morbidity and mortality. 2007 American Lung Association website http://www.lungusa.org/site/data and statistics
3 Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20 820-837
4 Niederman M S, Brito V. Pneumonia in the older patient. Clin Chest Med. 2007; 28 751-771
5 Fine M J, Smith M A, Carson C A et al.. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996; 275 134-141
6 Marston B J, Plouffe J F, File Jr T M et al.. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997; 157 1709-1718
7 Kaplan V, Clermont G, Griffin M F et al.. Pneumonia: still the old man's friend?. Arch Intern Med. 2003; 163 317-323
8 Lieberman D, Schlaeffer F, Boldur I et al.. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996; 51 179-184
9 Marrie T J, Peeling R W, Fine M J, Singer D E, Coley C M, Kapoor W N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996; 101 508-515
10 Ruiz M, Ewig S, Torres A et al.. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med. 1999; 160 923-929
11 Gleason P P, Meehan T P, Fine J M, Galusha D H, Fine M J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159 2562-2572
12 Brown R B, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims made database. Chest. 2003; 123 1503-1511
13 Weiss K, Tillotson G S. The controversy of combination vs. monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest. 2005; 128 940-946
14 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001; 161 1837-1842
15 Mufson M A, Sanek R J. Bacteremic pneumococcal pneumonia in one American city: a 20 year longitudinal study, 1978–1997. Am J Med. 1999; 107 34S-43S
16 Baddour L M, Yu V L, Klugman K P et al.. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170 440-444
17 Houck P M, MacLehose R F, Niederman M S, Lowery J K. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states: 1993,1995,1997. Chest. 2001; 119 1420-1426
18 British Thoracic Society . Guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001; 56(Suppl) 1-64
19 Feikin D R, Schuchat A, Kolczak M et al.. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health. 2000; 90 223-229
20 Farrell D J, Felmingham D. The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae . J Antimicrob Chemother. 2005; 56 795-797
21 Clinical and Laboratory Standards Institute .Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100–S18. Wayne, PA; Clinical and Laboratory Standards Institute 2008 http://Available at www.clsi.org
22 Plouffe J F, Breiman R F, Facklam R R. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA. 1996; 275 194-198
23 Metlay J P, Hofmann J, Cetron M S et al.. Impact of penicillin susceptibility on medical outcomes for adult patients with pneumococcal pneumonia. Clin Infect Dis. 2000; 30 520-528
24 Turett G S, Blum S, Fazal B A, Justman J E, Telzak E E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis. 1999; 29 321-327
25 Moroney J F, Fiore A E, Harrison L H et al.. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001; 32 797-805
26 Daneman N, McGeer A, Low D E. Toronto Bacterial Diseases Network . Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006; 43 432-438
27 Feldman R B, Rhew D C, Wong J Y, Charles R A, Goetz M B. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2 year experience from a veterans hospital. Arch Intern Med. 2003; 163 1718-1726
28 Vanderkooi O G, Low D E, Green K et al.. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005; 40 1288-1297
29 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a B-lactam–based empirical antibiotic regimen is associated with lower in-patient mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003; 36 389-395
30 Micek S T, Dunne M, Kollef M H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest. 2005; 128 2732-2738
31 Fine M J, Auble T E, Yealy D M et al.. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336 243-250
32 Lim W S, van der Erden M M, Laing R et al.. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58 377-382
33 Niederman M S, Feldman C, Richards G A. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J. 2006; 27 9-11
34 Aujesky D, Auble T E, Yealy D M et al.. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005; 118 384-392
35 Woodhead M, Blasi F, Ewig S et al.. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26 1138-1180
36 Metersky M L, Ma A, Bratzler D W, Houck P M. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004; 169 342-347
37 File Jr T M, Garau J, Blasi F et al.. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest. 2004; 125 1888-1901
38 Leroy O, Saux P, Bedos J P, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005; 128 172-183
39 Lodise T P, Kwa A, Cosler L, Gupta R, Smith R P. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007; 51 3977-3982
40 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164 637-644
41 Wachter R M, Flanders S A, Fee C, Pronovost P J. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med. 2008; 149 29-32
42 Welker J A, Huston M, McCue J D. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med. 2008; 168 351-356
43 Polgreen P M, Chen Y Y, Cavanaugh J E. An outbreak of severe Clostridium difficile–associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007; 28 212-214
44 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348 1737-1764
45 Bender J M, Ampofo K, Korgenski K et al.. Pneumococcal necrotizing pneumonia in Utah: does serotype matter?. Clin Infect Dis. 2008; 46 1346-1352

Michael S NiedermanM.D.

Division of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, Winthrop University Hospital

222 Station Plaza N., Ste. 509, Mineola, NY 11501

eMail: mniederman@winthrop.org